BioCentriq is thrilled to announce that Jackie Veivia-Panter is our new Chief Quality and Compliance Officer and has begun her role this week. Jackie has 30 years of experience in the pharmaceutical and cell therapy …

This month, BioCentriq hosted a webinar in collaboration with Phacilitate called Setting the Stage for Successful Manufacturing of Cell and Gene Therapies Webinar. It consisted of a panel of industry leaders giving much-needed lessons on …

Yesterday we celebrated the opening of our new GMP manufacturing facility, located adjacent to our pilot plant in South Brunswick. All employees were invited to join us at the Princeton Corporate Center in Monmouth Junction …

Topics Include the Bottlenecks in Personnel Capabilities and Facilities, Preclinical Pipeline Driving Capacity and Workforce Requirements, and Downstream Requirements  Newark, New Jersey– October 4, 2022 – BioCentriq, Inc.—a New Jersey-based, cell and gene therapy contract …

 BioCentriq added feeder cell irradiation capabilities to its impressive list of service offerings. In this article, we explain why we thought it was important to add these unique capabilities to our portfolio.  An Overview of …

This summer, BioCentriq ran its first internship program and recruited five talented students to work for ten weeks, allowing them to learn about the biotech industry, conduct research, and make lasting change within the company. …

The BioCentriq team will be attending this year’s Cell & Gene Therapy Manufacturing & Commercialization US Conference during Biotech Week, and two of our team members will be featured panelists. The conference will bring together …

On Friday, September 9, industry leaders and innovators gathered at NJIT for BioNJ’s 2022 Manufacturing Briefing. BioCentriq was proud to serve as a sponsor, and CEO Haro Hartounian, Ph.D., welcomed attendees with opening remarks along …

This July, Rutgers held its Bio Manufacturing Innovation Summit, which brought together advanced bio-manufacturing thought leaders, leading spin-out and growth company innovators, and decision-makers within the industry. The conference was meant to stimulate innovation, impact, …

A Message from CEO and Founder Haro Hartounian, Ph.D. 2022 has already been a year packed with growth and advancement, fueled by the need for regenerative medicine and the individuals working to bring new therapies …

BioCentriq, a subsidiary of the New Jersey Institute of Technology, was acquired by South Korean company GC for $73 million.

Dr. Haro Hartounian, SVP and General Manager of BioCentriq, was recognized as a Sector Star.